KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Payables (2016 - 2025)

AbbVie (ABBV) has disclosed Payables for 14 consecutive years, with $37.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 16.55% to $37.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $37.2 billion, a 16.55% increase, with the full-year FY2025 number at $37.2 billion, up 16.55% from a year prior.
  • Payables was $37.2 billion for Q4 2025 at AbbVie, roughly flat from $37.4 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $37.4 billion in Q3 2025 to a low of $20.6 billion in Q1 2021.
  • A 5-year average of $27.8 billion and a median of $28.2 billion in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: surged 62.12% in 2021, then increased 2.81% in 2024.
  • AbbVie's Payables stood at $22.7 billion in 2021, then increased by 11.84% to $25.4 billion in 2022, then rose by 20.66% to $30.6 billion in 2023, then rose by 4.23% to $31.9 billion in 2024, then rose by 16.55% to $37.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Payables are $37.2 billion (Q4 2025), $37.4 billion (Q3 2025), and $34.2 billion (Q2 2025).